{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:02:26Z","timestamp":1751515346418,"version":"3.41.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The management of neonatal jaundice is relatively straightforward; however, hemodynamic insults may still occur, particularly in very low birth weight infants. While phototherapy is effective, it may lead to prolonged hospitalization and potential adverse effects. This study investigates the efficacy of phenobarbitone in preventing neonatal hyperbilirubinemia in both term and preterm neonates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>We conducted a comprehensive search of PubMed, Web of Science, Embase, Cochrane Library, Scopus, and CINAHL to identify relevant articles published up to January 23, 2025. Study selection followed the PRISMA guidelines, and assessments of the risk of bias were performed. Data analysis was conducted using Review Manager 5.3, with mean difference (MD) and 95% confidence intervals (CI) calculated for continuous variables, while risk ratios (RR) were estimated for binary variables.<\/jats:p>\n            <jats:p>We included randomized controlled trials (RCTs) that investigated the effects of phenobarbitone on neonatal hyperbilirubinemia. The primary outcomes assessed were phototherapy duration, the need for exchange transfusion, peak bilirubin levels, the need of phototherapy, and cumulative weight loss. The extracted data encompassed key study characteristics along with an evaluation of the risk of bias 1.0 tool and Level of Evidence was summarized using GRADE guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result<\/jats:title>\n            <jats:p>A total of 41 articles were identified through searches of six databases. After removing duplicates, 23 articles remained. Based on title and abstract screening, 15 were excluded. An additional 3 articles were excluded for not meeting the inclusion criteria. Five studies, including 590 newborns, were identified and included in the meta-analysis. This meta-analysis discovered significant changes in phototherapy duration, measured in hours (mean difference (MD) \u201324.51 (95% CI \u201334.08, \u201314.94), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) with low heterogeneity, exchange transfusion(Risk ratio(RR) 0.32 (95% CI 0.16, 0.61), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) with low heterogeneity, peak bilirubin level(MD \u20132.35 (95% CI \u20132.96, \u20131.74), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) with low heterogeneity, need of phototherapy (RR 0.75 (95% CI 0.66, 0.85), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) with low heterogeneity. There was not a significant change in weight loss (MD 0.15 (95% CI -0.76, 1.07), <jats:italic>p<\/jats:italic>\u2009=\u20090.74) with low heterogeneity. Only one of these studies reported side effects of phenobarbitone (Pediatric Res 51:399A, 2002).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Phenobarbitone might be applied in unconjugated neonatal hyperbilirubinemia to reduce the peek bilirubin level, phototherapy duration, and reduce the chance of exchange transfusion and phototherapy treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PROSPERO registration number<\/jats:title>\n            <jats:p>CRD42025636128.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12887-025-05844-w","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:21:39Z","timestamp":1751430099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of phenobarbitone on neonatal hyperbilirubinemia, a systematic review and meta-analysis of randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbo","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinfa","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"5844_CR1","doi-asserted-by":"crossref","unstructured":"FF. R. Current drug treatment options in neona tal hyperbilirubinaemia and the prevention of kernicterus. 1998;56(1):23\u201330. 1998;Drugs.","DOI":"10.2165\/00003495-199856010-00003"},{"issue":"5","key":"5844_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197113","volume":"13","author":"L Zhang","year":"2018","unstructured":"Zhang L. Severe neonatal hyperbilirubinemia induces temporal and occipital lobe seizures. PLoS One. 2018;13(5): e0197113. https:\/\/doi.org\/10.1371\/journal.pone.0197113.","journal-title":"PLoS One"},{"key":"5844_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051240","author":"S Iijima","year":"2022","unstructured":"Iijima S. Exchange transfusion in neonatal sepsis: a narrative literature review of pros and cons. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11051240.","journal-title":"J Clin Med"},{"key":"5844_CR4","first-page":"5","volume":"5","author":"BAP Kumar","year":"2012","unstructured":"Kumar BAP, Chorishi A, Dhaneria M. Fenofi-brate: A novel approach in treating uncomplicated neonatal hyperbilirubinemia. Peoples J Sci Res. 2012;5:5\u20138.","journal-title":"Peoples J Sci Res"},{"key":"5844_CR5","doi-asserted-by":"crossref","unstructured":"KL. T. The pattern of bilirubin response of pho totherapy for neonatal hyperbilirubinemia.. Pediatr Res. 1982;16(8):670\u20134.","DOI":"10.1203\/00006450-198208000-00018"},{"issue":"2","key":"5844_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/NPM-210847","volume":"15","author":"SAHMM Nouri","year":"2022","unstructured":"Nouri SAHMM, Moghaddam YN, Rad AH, Zarkesh M. Therapeutic effects of synbiotic on neonates with gestational age over 34 weeks admitted for jaundice. J Neonatal Perinatal Med. 2022;15(2):327\u201333. https:\/\/doi.org\/10.3233\/NPM-210847.","journal-title":"J Neonatal Perinatal Med"},{"key":"5844_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0022-3476(71)80203-2","volume":"79","author":"OSMH Valdes","year":"1971","unstructured":"Valdes OSMH, Shumway CN, Draper DAHA. Controlled clinical trials of phenobarbital and\/or light in reducing neonatal hyperbilirubinemia in a predominantly Negro population. J Pediatr. 1971;79:1015\u20137.","journal-title":"J Pediatr"},{"key":"5844_CR8","first-page":"43","volume":"11","author":"MNP Singh","year":"1974","unstructured":"Singh MNP. Effect of phenobarbitone on physiological jaundice. Indian Pediatr. 1974;11:43\u20135.","journal-title":"Indian Pediatr"},{"key":"5844_CR9","unstructured":"Maisels MJ. Jaundice. In: Avery GB F, MA MM. Neonatology:Pathophysiology and Management of Newborns. 5th ed Philadephia: Lippencott Williams and Wilkins;. 1999;p 765\u2013820."},{"key":"5844_CR10","doi-asserted-by":"publisher","unstructured":"Falsaperla R ML, Pavone P, Barbagallo M, Vitaliti G, Ruggieri M,, al. e. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behav Neurol. 2019;2019:3683548. https:\/\/doi.org\/10.1155\/2019\/3683548.","DOI":"10.1155\/2019\/3683548"},{"key":"5844_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPTTJ Higgins","year":"2019","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. New York: Wiley; 2019.","edition":"2"},{"issue":"3","key":"5844_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1213\/ANE.0000000000004014","volume":"128","author":"TR Vetter","year":"2019","unstructured":"Vetter TR. Systematic review and meta-analysis: sometimes bigger is indeed better. Anesth Analg. 2019;128(3):575\u201383. https:\/\/doi.org\/10.1213\/ANE.0000000000004014.","journal-title":"Anesth Analg"},{"key":"5844_CR13","unstructured":"Kumar R, Narang A, Kumar P, Garewal G. Phenobarbitone prophylaxis for neonatal jaundice in babies with birth weight 1000\u20131499 grams [Journal article]. Indian pediatrics. 2002;39(10):945\u2010951. Cited in: Pubmed; PMID CN-00411331."},{"key":"5844_CR14","doi-asserted-by":"publisher","unstructured":"Hussain Z, Kainth UPS, Thakrani K. Comparative Study of Prophylactic and Therapeutic Role of Phenobarbitone in the Hyperbilirubinemia in V.L.B.W Babies with birth weight 1000\u20131499 grams and their outcome [Journal article]. Journal of cardiovascular disease research. 2022;13(6):493\u2010497. https:\/\/doi.org\/10.31838\/jcdr.2022.13.06.54. Cited in: Pubmed; PMID CN-02612129.","DOI":"10.31838\/jcdr.2022.13.06.54"},{"key":"5844_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"A cochrane handbook for systematic reviews of interventions","author":"JTJ Higgins","year":"2019","unstructured":"Higgins JTJ, Chandler J, Cumpston M, Li T, Page MJ. A cochrane handbook for systematic reviews of interventions. Chichester, (UK): John Wiley & Sons; 2019."},{"key":"5844_CR16","unstructured":"Aggarwal R, Rekha S, D'Souza FS. Postnatal phenobarbitone for preventing hyperbilirubinaemia in newborns with ABO incompatibility [3] [Letter]. Natl Med J India. 2001;14(6):378. English."},{"key":"5844_CR17","doi-asserted-by":"crossref","unstructured":"<early high dose phenobarbital tre source j pediatr us so 1988 jan 112 1 81 86.pdf>. 1988.","DOI":"10.1016\/S0022-3476(88)80127-6"},{"key":"5844_CR18","unstructured":"Arya VB, Agarwal R, Aggarwal R, Paul VK, Deorari AK. Efficacy of oral phenobarbitone in at-risk neonates in decreasing neonatal hyperbillirubinemia [Journal article]. Pediatric research. 2002;51(4):399A. Cited in: Pubmed; PMID CN-00419375."},{"key":"5844_CR19","doi-asserted-by":"crossref","unstructured":"<the impact of prenatal drug exposure on the neonate source obstet gyn clin n am so 1998 mar 25 1 169 .pdf>.","DOI":"10.1016\/S0889-8545(05)70364-8"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05844-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:21:46Z","timestamp":1751430106000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-05844-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5844"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05844-w","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a meta-analysis, ethical approval is not necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"504"}}